CONSENT TO GENETIC TESTING THROUGH A RESEARCH STUDY

Similar documents
INFORMATION BROCHURE - ALLOCATE

UNIVERSITY OF CALIFORNIA, SAN FRANCISCO CONSENT TO PARTICIPATE IN A RESEARCH STUDY

About this consent form. Why is this research study being done? Partners HealthCare System Research Consent Form

Vanderbilt University Institutional Review Board Informed Consent Document for Research. Name of participant: Age:

INFORMATION AND CONSENT FORM

Screening for Genes for Hereditary Breast and Ovarian Cancer in Jewish Women

UNIVERSITY OF PENNSYLVANIA RESEARCH SUBJECT INFORMED CONSENT AND HIPAA AUTHORIZATION FORM

VERBAL CONSENT TO PARTICIPATE IN A RESEARCH STUDY AND HIPPA AUTHORIZATION

Research Ethics Board Research Consent Form Genetic Analysis

BRCA genes and inherited breast and ovarian cancer. Information for patients

Hypertrophy of liver Neonatal hypoglycemia Omphalocele Large for gestational age Other:

Northwestern University Department of Urology CONSENT FORM AND AUTHORIZATION FOR RESEARCH

Title of Research Study: Discovery and Validation of Biomarkers for Lichen Sclerosus

About this consent form

RESEARCH CONSENT FORM

UNIVERSITY OF PENNSYLVANIA HEALTH SYSTEM

UNIVERSITY OF CALIFORNIA, SAN FRANCISCO CONSENT TO PARTICIPATE IN A RESEARCH STUDY

Genetic testing for breast cancer susceptibility

YES. If yes, indicate what types of tumors/polyps and age of onset:

Subject Name: Sponsor Consent Tmplt Date: Version 2 (17-Jul-2014) Unit Number:

IRB Approved: 09-Jan-2015 To: 08-Jan-2016

University of Pennsylvania RESEARCH Subject Informed Consent Form AND RESEARCH SUBJECT HIPAA AUTHORIZATION

VANISH Vasopressin vs Noradrenaline as Initial therapy in Septic shock

CONSENT FORM. The Full Study Title Should Be Placed Here. Principal Investigator: Dr. John Smith Sub-Investigator: Dr. Jane Smith

UNIVERSITY OF CALIFORNIA, SAN FRANCISCO CONSENT TO BE IN RESEARCH

UNIVERSITY HOSPITALS CASE MEDICAL CENTER CONSENT FOR INVESTIGATIONAL STUDIES (v )

UNIVERSITY OF PENNSYLVANIA HEALTH SYSTEM. A5272 Version 2.0, 5/19/11: Oral HPV Shedding and Oral Warts After Initiation of Antiretroviral Therapy

IRB USE ONLY Approval Date: September 10, 2013 Expiration Date: September 10, 2014

IRB Approval From: 3/8/2010 To: 10/28/2010

BRCAnowTM It s Your Decision

Information leaflet for for men from families with a known alteration in the BRCA1/2 gene. BRCA1 and BRCA2 for men

Understanding and Managing Lynch Syndrome

Hereditary Breast and Ovarian Cancer (HBOC) Information for individuals and families

patient guide Hereditary Cancer genetic testing panels Because knowing your risk can mean early detection and prevention

Hereditary Gynecologic Cancer

We are inviting you to participate in a research study/project that has two components.

HREC/17/RCHM/334 RCH HREC 37278A. ANZ CLARITY Establishment of a National Juvenile Idiopathic Arthritis Biobank.

The Johns Hopkins Bloomberg School of Public Health

TumorNext-HR D. patient guide. a test for ovarian cancer patients to identify hereditary and tumor-specific mutations

PrEP Impact Trial: A Pragmatic Health Technology Assessment of PrEP and Implementation. Part 1

COLLECTION AND BANKING OF BIOLOGICAL SAMPLES AND COLLECTION OF CLINICAL DATA FROM PERSONS WITH BLOOD DISORDERS

GeneticsNow TM. A Guide to Testing Hereditary Conditions in Women & Men. Patient & Physician Information

TumorNext-HR D. patient guide. a test for ovarian cancer patients to identify hereditary and tumor-specific mutations

Language for Consent Forms

patient guide MelanomaNext genetic testing for hereditary melanoma Because knowing your risk can mean early detection and prevention

Epilepsy Genetics Service Kings College Hospital & St Thomas s Hospital, London

BRCA1 and BRCA2. patient guide. genetic testing for hereditary breast and ovarian cancer (hboc)

We are inviting you to participate in a research study/project that has two components.

University of California, San Diego. Colesevelam versus placebo in the treatment of nonalcoholic steatohepatitis

UNIVERSITY OF PENNSYLVANIA HEALTH SYSTEM

Sequencing. Deletion/Duplication Analysis. How Does Genetic Testing for Cancer Work?

I have ovarian cancer

patient guide PancNext genetic testing for hereditary pancreatic c a ncer Because knowing your risk can mean early detection and prevention

GENETIC TESTING: WHAT DOES IT REALLY TELL YOU? Lori L. Ballinger, MS, CGC Licensed Genetic Counselor University of New Mexico Cancer Center

Lynch Syndrome. patient guide. genetic testing for hereditary colorectal and uterine cancer

Participant Information Leaflet

patient guide ProstateNext genetic testing for hereditary prostate cancer Because knowing your risk can mean early detection and prevention

A study of Standard and New Antiepileptic Drugs SANAD-II

Russell-Silver syndrome (RSS)

Talking Genomes with Your Patients. Meagan Cochran, MS, CGC Certified Genetic Counselor HudsonAlpha Institute for Biotechnology

3/6/2017-6/15/2017 Permission to Take Part in a Human Research Study Page 1 of 6

Northwestern University. Consent Form and HIPAA Authorization for Research

Contents. Introduction. Introduction 03

INFORMED CONSENT REQUIREMENTS AND EXAMPLES

Adult Patient Information and Consent Form

Consultation Questionnaire

Understanding My Pap Test Results

Information leaflet for women with an increased lifetime risk of breast and ovarian cancer. Hereditary Breast and Ovarian Cancer (HBOC)

I have ovarian cancer

OvaNext. patient guide. genetic testing for hereditary breast, ovarian, and uterine cancer

patient guide BreastNext genetic testing for hereditary breast cancer Because knowing your risk can mean early detection and prevention

THE KRONGRAD INSTITUTE Sep 25, 2008 WIRB RESEARCH SUBJECT INFORMATION AND CONSENT FORM

Kimberly Anne Hoffman, L.Ac. (HIPAA) CONSENT TO THE USE AND DISCLOSURE OF HEALTH INFORMATION FOR TREATMENT, PAYMENT, OR HEALTHCARE OPERATIONS NAME

Royal Marsden Breast Unit. BRCA testing learning resources pack (MCG LRP1)

Research Consent Form Newton-Wellesley Hospital 2014 Washington Street Newton, MA 02462

NCI Community Oncology Research Program Kansas City (NCORP-KC)

Suspected CANcer (SCAN) Pathway Information for patients

Please take time to read this document carefully. It forms part of the agreement between you and your counsellor and Insight Counselling.

Research Consent Form for Parents of a non-capable child Genetic Analysis

Patient Information Sheet

WHAT YOU NEED TO KNOW ABOUT DONATING SPERM, EGGS OR EMBRYOS

UNIVERSITY OF WISCONSIN-MADISON Research Participant Information and Consent Form

Consent and Authorization Document

BRCA1 & BRCA2 GeneHealth UK

patient guide CancerNext genetic testing for hereditary cancer Because knowing your risk can mean early detection and prevention

GeneHealth BRCA 1&2_ qxp_Layout 1 21/02/ :44 Page 3 BRCA1 & BRCA2 GeneHealth UK

UNIVERSITY OF PENNSYLVANIA HEALTH SYSTEM. A Pilot Study for Collection of Anti-Zika Immune Plasma

Clinical Genetics Welcome to Clinical Genetics

Human Subject Institutional Review Board Proposal Form

Be on the TEAM: Teenagers against Meningitis

12: BOWEL CANCER IN FAMILIES

What Are Genes And Chromosomes?

RESEARCH INVOLVING HUMAN PARTICIPANTS EXPEDITED/FULL APPLICATION

People s Panel today. You can use your views and experiences to help us help other young people.

Genetic Counselor: Hi Lisa. Hi Steve. Thanks for coming in today. The BART results came back and they are positive.

Genetic Tests for Diagnosis Of Breast Cancer

This information explains the advice about familial breast cancer (breast cancer in the family) that is set out in NICE guideline CG164.

Please do not hesitate to contact us (see below) if there is anything that is not clear or if you would like more information.

Therapeutic Sperm Banking

patient guide RenalNext genetic testing for hereditary kidney cancer Because knowing your risk can mean early detection and prevention

Transcription:

CONSENT TO GENETIC TESTING THROUGH A RESEARCH STUDY Title Principal Investigator Genetic Counsellor Prevent Ovarian Cancer Program: Systematic identification of high-risk women for ovarian cancer prevention Marcus Bernardini, MD Jeanna McCuaig, MSc, CGC, CCGC Introduction You are being offered genetic testing as part of the research study Prevent Ovarian Cancer Program (POCP) at the Princess Margaret Cancer Centre. Please read this explanation about the risks and benefits before you decide if you would like to provide a blood sample. You should take as much time as you need to make your decision. You should ask the genetic counsellor or POCP staff to explain anything that you do not understand. Before you make your decision, feel free to talk about this study with anyone you wish. Please make sure that all of your questions have been answered before signing this consent form. Participation in this study is voluntary. Background and Purpose Up to 20-25% of women with high grade serous ovarian cancer have a hereditary type of cancer, which means that their family members may have an increased risk to develop cancer. In Ontario, genetic testing to look at the BRCA1 and BRCA2 genes, which are the genes most often associated with hereditary ovarian cancer, is available to any woman with a diagnosis of serous ovarian cancer regardless of her family history. Unfortunately most women with serous ovarian cancer have not had this testing done. This means that their female relatives may not know that they have an inherited risk to develop ovarian cancer. Finding women who have an increased risk to develop ovarian cancer will allow us to give them information on how they can reduce their risk. Study Design & Procedures After a genetic counselling session, you will provide a blood sample for genetic testing. One tube (about one teaspoon) of blood can be collected at any LifeLabs laboratory. The genetic test will look at the BRCA1 and BRCA2 genes as well as a panel of 50 other genes that may have a role in the development of ovarian and/or other cancers. This test will be completed at the Princess Margaret Advanced Molecular Diagnostic Lab. The laboratory will report genetic changes that are likely to prevent the gene from working properly. These changes may increase a person s risk to develop cancer. Version date May 11, 2015 Page 1 of 5

When results are available, a genetic counsellor will review your test results with you. If appropriate, the genetic counsellor will send a referral to specialists for follow-up care. You will be provided with a copy of your test results and written information explaining them. A detailed note will also be sent to your family doctor. Limitations of the Test A negative test result does not rule out hereditary cancer. This test will not tell you whether or not you have or will develop cancer. It may tell you if your risk of certain cancers is higher than the average Canadian woman. There is a small chance (less than 1%) that a mutation in the BRCA1 or BRCA2 genes may be missed using current technologies Risks of Having the Test Providing a blood sample can cause minor discomfort. In some cases, bruising or discoloration near the site of needle insertion may occur. Some women who have this test may learn that they have an increased risk to develop ovarian cancer in their lifetime, which may cause increased anxiety. This test may provide information about genes that are still being studied and/or genes where doctors have no clear guidelines for cancer screening and prevention. Some individuals may receive uncertain results, which means that a change in a gene has been found, but is not clear if that change increases cancer risks or not. Benefits of Having the Test This test may identify that you have an increased risk to develop ovarian and/or other cancer. Knowing this information will help you to learn and consider appropriate options for increased cancer screening and/or cancer risk reduction. Based on the results of your genetic test, the option of genetic testing may become available to your family members. They also can learn more about their condition and consider appropriate options such as cancer screening and/or cancer risk reduction. This test may help you to understand your family history of cancer. This test may determine that, based on available scientific data, your risk of developing ovarian cancer may be similar to that of the average Canadian woman. The Type of Results to be Reported This genetic test includes a panel of 52 genes that may be associated with an increased risk to develop cancer. Some genes are known to cause an increased risk of ovarian and/or other cancers and screening guidelines are available. Other genes are thought to cause an increased risk of ovarian and/or other cancer but the exact cancer risks are still being determined and screening guidelines are not yet available. Please initial beside the information that you would like to know. Version date May 11, 2015 Page 2 of 5

You will have the option of receiving results on the following genes. Please indicate your choice on the last page of this document (consent). A) BRCA1 and BRCA2 only. I understand that variant, or uncertain, results in these genes will be reported. B) Genes that are known to increase the risk of ovarian and other cancers and where established guidelines for cancer screening are available. I understand that variant, or uncertain, results in these genes will be reported. C) Genes that are thought to increase the risk of ovarian and other cancers but where established guidelines for cancer screening may not be available. D) Genes that are known to increase the risks of other cancers (but not ovarian) and where established guidelines for cancer screening are available. Confidentiality & Data Storage The laboratory will report the test results to members of the Prevent Ovarian Cancer Program. You will be given a copy of your test results. The genetic test results will become part of your medical record and some individuals may have legal access to this information. Sample Storage If you agree, the laboratory may store any remaining sample(s) for future product development or research purposes. You will not receive any royalties, resultant payments, benefits or rights to products or discoveries. Voluntary Participation Your decision to have genetic testing is entirely voluntary. If you consent to genetic testing, but later decide that you do not wish to receive your genetic test results for any reason, stated or unstated, you may withdraw your consent for genetic testing. All results will be entered into your medical record upon completion of the genetic test so it is important that you contact the genetic counsellor immediately if you do not wish to know your genetic testing results. If you decide you no longer want your samples stored for any reason, stated or unstated, they can be destroyed at any time. Version date May 11, 2015 Page 3 of 5

Questions About the Study If you have any questions, concerns or would like to speak to the genetic counsellor for any reason, please leave a message for Jeanna McCauig at 1-866-330-0180 or email preventovariancancer@uhnresearch.ca. Please do not communicate private or sensitive information in email. If you have any questions about voluntary participation, confidentiality, or questions related to the overall conduct of the study, please refer to the Voluntary participation, Confidentiality, or Questions about the Study sections of the POCP Study consent form. If you have any questions about your rights as a research participant or have concerns about this study, call the Chair of the University Health Network Research Ethics Board (REB) or the Research Ethics office number at 416-581-7849. The REB is a group of people who oversee the ethical conduct of research studies. These people are not part of the study team. Everything that you discuss will be kept confidential. Please keep one signed copy of this consent form for your records. Version date May 11, 2015 Page 4 of 5

Consent I would like my genetic test result to include information on the following genes: (Please indicate with X. You may select more than one) A) BRCA1 and BRCA2 only. I understand that variant, or uncertain, results in these genes will be reported. B) Genes that are known to increase the risk of ovarian and other cancers and where established guidelines for cancer screening are available. I understand that variant, or uncertain, results in these genes will be reported. C) Genes that are thought to increase the risk of ovarian and other cancers but where established guidelines for cancer screening may not be available. D) Genes that are known to increase the risks of other cancers (but not ovarian) and where established guidelines for cancer screening are available. Your genetic test results will not be shared with any family members unless we cannot contact you to provide you with your results (death or illness). In this case, your genetic test results may be disclosed to the biological relative listed below. If you decline to know your genetic test results, this relative will not be contacted. Biological Relative s Name (print) Phone number This genetic test has been explained to me and any questions I had have been answered. I agree to provide a blood sample for genetic testing through the Prevent Ovarian Cancer Program. If you do not want your sample to be stored, please initial below: I do not want my remaining sample to be stored. Please destroy any remaining sample once the final report has been issued. Study Participant s Name (print) Signature Date Name of Person Obtaining Consent (print) Signature Date My signature means that I have explained the genetic test to the participant named above. I have answered all questions. Version date May 11, 2015 Page 5 of 5